Bayer
NEWS
Here’s a look at who shook things up in the world of pharma and biotech this week.
Following AbbVie Lawsuit, Government Scrutinizes Industry-Provided Drug Educational Support Services
A federal investigation is underway into whether or not the nursing and other medical services provided by some pharmaceutical companies to doctor’s offices actually violate the law due to serving an illegal commercial service.
Shares of OncoMed Pharmaceuticals are falling this morning after the company announced that Celgene has walked away from a deal to license the company’s bispecific antibody navicixizumab.
TissUse has signed a collaboration agreement with Bayer to develop a highly innovative liver-endocrine tissues assay using TissUse’s Multi-Organ-Chip (MOC) technology.
Hemophilia A patients have another treatment option. This morning the U.S. Food and Drug Administration gave the nod to Bayer AG’s new treatment, Jivi (BAY94-9027).
Janssen Pharmaceutical and Bayer saw the good, the bad and the potential for ugly this week with their blockbuster blood-thinner Xarelto (rivaroxaban). The drug gained approval for a new indication in Europe, failed a late-stage trial and is staring down the barrel of patent loss in 2023 while battling legal threats.
Evotec AG and Haplogen GmbH have been long-term collaboration partners. The companies announced that Haplogen will enter into a multi-year drug discovery and development deal with Bayer AG to focus on pulmonary diseases like chronic obstructive pulmonary disease (COPD).
Almirall, headquartered in Barcelona, Spain, announced it is buying five dermatology products from Allergan. Those include Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid), Cordran Tape (fludroxycortide) and Seysara (sarecycline).
Recent studies in early diagnostics underline just how much focus medical technology companies are making on developing different modalities for very early cancer diagnosis. Here are just some recent examples.
JOBS
IN THE PRESS